Palvella Therapeutics has appointed Matt Pauls, an experienced biotech executive with over 25 years in rare disease drug development and commercialization, to its Board of Directors. Pauls brings leadership from companies like Savara, Soleno, and Insmed, and will support Palvella's upcoming U.S. launch of QTORIN™ rapamycin and its pipeline for rare skin diseases and vascular malformations. This move strengthens Palvella's expertise as it advances therapies with no FDA-approved options. Pauls expressed enthusiasm about contributing to Palvella's growth during this pivotal phase.
American Airlines CEO Robert Isom has sold 335,000 shares of the company, generating $4.3 million from the transaction. This sale could indicate a personal financial decision or a strategic move by the CEO, which investors might watch closely for any...
BlackRock's iShares Bitcoin Trust saw a $165.4 million outflow in the week ending October 16, 2026, making up 72% of the $228.4 million total Bitcoin ETF outflows that week. Despite this, Bitcoin's price remains strong, trading around $81,141, up 6.8...
Occidental Petroleum's stock rose over 50% in the past year, driven by higher oil prices and improving fundamentals amid geopolitical tensions. Warren Buffett's Berkshire Hathaway holds a 26.9% stake and recently acquired Occidental's OxyChem busines...
Bitcoin exchange-traded funds (ETFs) recorded net inflows of $355 million in 2026, maintaining a positive balance for the year after turning positive again in September. This trend continued through October 18, signaling renewed investor interest in ...
Higher interest rates have expanded net interest spreads for agency mortgage REITs without reducing their dividend cash flow, while equity REIT dividend yields have returned to levels last seen in March 2020. Commercial mortgage REITs benefit from in...
